Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr 7;221(9):1390-1393.
doi: 10.1093/infdis/jiz283.

Salvage Antiretroviral Therapy: Time for "DeNUKElearization"?

Martin Hoenigl  1 , Susan J Little  1
Affiliations
Editorial

Salvage Antiretroviral Therapy: Time for "DeNUKElearization"?

Martin Hoenigl et al. J Infect Dis. .
No abstract available

Keywords: HIV-1; antiretroviral therapy; drug resistance; randomized controlled trial; salvage therapy; treatment-experienced participants.

PubMed Disclaimer

Comment on

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 5 December 2019.
    1. Saag MS, Benson CA, Gandhi RT, et al. . Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA panel. JAMA 2018; 320:379–96. - PMC - PubMed
    1. Negredo E, Miró O, Rodríguez-Santiago B, et al. . MULTINEKA Study Group Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009; 49:892–900. - PubMed
    1. Stecher M, Chaillon A, Eis-Hubinger AM, et al. . Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. Clin Microbiol Infect 2019; 25:253.e1–4.. - PMC - PubMed
    1. Raffi F, Babiker AG, Richert L, et al. . NEAT001/ANRS143 Study Group Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384:1942–51. - PubMed

Substances